Equities

Champions Oncology Inc

Champions Oncology Inc

Actions
  • Price (EUR)4.22
  • Today's Change0.000 / 0.00%
  • Shares traded500.00
  • 1 Year change-15.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Apr 30 2024202420232022
ASSETS
Cash And Short Term Investments2.62109.01
Total Receivables, Net9.538.019.51
Total Inventory------
Prepaid expenses1.501.331.14
Other current assets, total------
Total current assets141920
Property, plant & equipment, net121515
Goodwill, net0.340.340.34
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.190.020.02
Total assets263435
LIABILITIES
Accounts payable5.805.332.87
Accrued expenses3.503.483.47
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total121311
Total current liabilities222217
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total6.497.948.80
Total liabilities283026
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital838281
Retained earnings (accumulated deficit)(85)(77)(72)
Treasury stock - common(0.71)(0.07)--
Unrealized gain (loss)------
Other equity, total------
Total equity(1.9)4.649.10
Total liabilities & shareholders' equity263435
Total common shares outstanding141414
Treasury shares - common primary issue0.120.010
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.